CVRx
NASDAQ: CVRXAustin, US · Delaware corporation · 7 known investors
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
Founders & leadership
CP
Craig PalmerExecutive Officer
GP
Geoff PardoDirector
NY
Nadim YaredExecutive Officer, Director
DB
Dean Bruhn-DingExecutive Officer
JB
John BrintnallExecutive Officer
LG
Liz GalleExecutive Officer
JM
John M. NehraDirector
KK
Kadir KadhiresanDirector
AB
Ali BehbahaniDirector
JS
Joseph SlatteryDirector
TH
Tom HeymanDirector
Investors · 7
Treo Ventures, LlcMinneapolis
Windham Capital PartnersNew York
Windham Venture PartnersNew York · $1M – $5M
Ysios CapitalBarcelona · $5.4M – $21.6M
Hatteras Venture PartnersreportedResearch Triangle · $500K – $4M
New Enterprise Associates (NEA)reportedMenlo Park · $200K – $40Mvia Ali Behbahani · board
Vensana Capitalreported · 2 sourcesMinneapolis
Reported raises · per SEC filings
Form D private placements▶$50MraisedJul 2020 · 21 investors · Other Health CareRule 506(b)
▶$50MraisedJul 2020 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John BrintnallExecutive Officer
- Elizabeth GalleExecutive Officer
- Dean Bruhn-DingExecutive Officer
- Kirk NielsenDirector
- Ali BehbahaniDirector
- Kadir KadhiresanDirector
- Mudit K. JainDirector
- Joseph SlatteryDirector
- Nadim YaredExecutive Officer, Director
- Geoff PardoDirector
- John M. NehraDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$75.3MraisedMay 2019 · 20 investors · Other Health CareRule 506(b)
▶$75.3MraisedMay 2019 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Craig PalmerExecutive Officer
- Geoff PardoDirector
- Nadim YaredExecutive Officer, Director
- Dean Bruhn-DingExecutive Officer
- John BrintnallExecutive Officer
- Liz GalleExecutive Officer
- John M. NehraDirector
- Kadir KadhiresanDirector
- Ali BehbahaniDirector
- Joseph SlatteryDirector
- Tom HeymanDirector
- Offering amount
- $93M
- Amount sold
- $75.3M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- CVRx enables first commercial Barostim implant in Washington state for heart failure treatmenttradersunion.com · 2026
- News release: CVRx® Raises $50 Million in New Equity Financing - CVRxbarostim.com · 2020
- CVRx's $93 million financing tops recent funding news in Minneapolishoodline.com · 2019
- CVRx Raises Additional $12M in Series F Financing - FinSMEsfinsmes.com · 2013
- CVRx raises $29.6M for hypertension device | Fierce Biotechfiercebiotech.com · 2013